keyword
MENU ▼
Read by QxMD icon Read
search

neutropenia over view

keyword
https://www.readbyqxmd.com/read/27178240/venetoclax-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-with-17p-deletion-a-multicentre-open-label-phase-2-study
#1
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G Wierda
BACKGROUND: Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response. Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia...
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/25731486/-nanoparticle-albumin-bound-paclitaxel-for-unresectable-or-recurrent-gastric-cancer
#2
Tomohisa Egawa, Takeshi Kemmochi, Shin Nishiya, Koki Mihara, Yasuhiro Ito, Atsushi Nagashima
The efficacy and safety of nanoparticle albumin-bound paclitaxel(nab-paclitaxel)administered every 3 weeks for unresectable or recurrent gastric cancer was evaluated retrospectively. Nab-paclitaxel was intravenously administered at 260 mg/ m² on day 1 of each 21-day course without anti-allergic premedication until disease progression or discontinuation. Nine patients received nab-paclitaxel. The overall response rate was 11.1%, and the disease control rate was 55.6%. Grade 3/4 toxicities included neutropenia(44...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/24688087/phase-i-study-of-carboplatin-combined-with-pemetrexed-for-elderly-patients-with-advanced-non-squamous-non-small-cell-lung-cancer
#3
Hiroaki Takeoka, Kazuhiko Yamada, Koichi Azuma, Yoshiaki Zaizen, Fumie Yamashita, Tsukasa Yoshida, Yoshiko Naito, Yusuke Okayama, Maki Miyamoto, Tomoaki Hoshino
OBJECTIVE: The primary objective of this study was to evaluate the safety and tolerability of carboplatin plus pemetrexed for elderly patients (≥75 years) with chemotherapy-naïve advanced non-squamous non-small cell lung cancer. METHODS: Patients received escalated doses of carboplatin at an area under the concentration-time curve of 4 (Level 1) or 5 (Level 2) plus pemetrexed (500 mg/m(2)) every 3 weeks for a maximum of six cycles. Dose escalation was decided according to whether dose-limiting toxicity occurred in the first cycle of chemotherapy...
May 2014: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/23073758/phase-ii-open-label-study-of-sunitinib-in-patients-with-advanced-breast-cancer
#4
MULTICENTER STUDY
Denise A Yardley, E Claire Dees, Stephen D Myers, Sherry Li, Paul Healey, Zhixiao Wang, Marla J Brickman, Jolanda Paolini, Kenneth A Kern, Dennis L Citrin
This multicenter, open-label phase II study was conducted to evaluate sunitinib monotherapy in patients with either metastatic or locoregionally recurrent advanced breast cancer. Patients received sunitinib 37.5 mg on a continuous daily dosing schedule. The primary endpoint was objective response rate (ORR); the predefined target ORR was 25 %. All 83 patients enrolled into the study received study treatment. The majority of patients (90 %) had metastatic disease; 92 % had received prior systemic therapies, and 60 % had received two or more regimens for early and/or advanced disease...
December 2012: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/23070203/management-of-suspected-lyme-borreliosis-experience-from-an-outpatient-parenteral-antibiotic-therapy-service
#5
B White, R A Seaton, T J Evans
OBJECTIVES: Lyme borreliosis (LB) is the most common human tick-borne infection in Europe and the USA. In this study we set out to analyse the outcome of patients treated for Lyme disease via outpatient parenteral antibiotic therapy (OPAT) and the appropriateness of this treatment using current guidelines. METHODS: This was a retrospective review of all patients with suspected LB managed via OPAT in Glasgow in 2000-11. RESULTS: Of 72 patients treated for suspected LB, 35 patients (49%) were treated in accordance with guidelines and 36 (50%) were treated with no specific guidelines...
February 2013: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/22304013/evaluation-of-infection-control-advice-for-patients-at-risk-of-chemotherapy-induced-neutropenia-in-2-pediatric-oncology-centers-cape-town-south-africa-and-newcastle-upon-tyne-uk
#6
MULTICENTER STUDY
Andrea Forman Woolner, Alan Davidson, Rod Skinner, Derek King
Childhood cancers are treated with myelotoxic chemotherapy. Resultant neutropenia can lead to life-threatening infections. There is no consistent guidance on infection control precautions for neutropenic patients who are not yet febrile or infected. Although it is not possible to eradicate infection risk, it is conceivable that the risk could be reduced by effective infection prevention. This study compared infection control measures advised to pediatric and adolescent oncology patients receiving chemotherapy in 2 centers (Cape Town, South Africa, and Newcastle, UK)...
February 2012: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/21987144/cutaneous-adverse-reactions-to-chemotherapy-with-taxanes-the-dermatologist-s-point-of-view
#7
Aline Donati, Luiz Guilherme Martins Castro
Chemotherapy with taxanes has recently become part of the treatment for many advanced neoplastic diseases, specially breast and lung cancer. Their main noncutaneous adverse reactions include neutropenia and mucositis, which eventually lead to drug discontinuation. Cutaneous adverse reactions are frequent and significantly interfere with the patient's quality of life. Treatments are poorly effective, but special recommendations may improve symptoms and prevent relapses requiring drug rechallenge.
July 2011: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/20643629/clozapine-for-treatment-resistant-schizophrenia-national-institute-of-clinical-excellence-nice-guidance-in-the-real-world
#8
Ann M Mortimer, Praveen Singh, Charles J Shepherd, Junais Puthiryackal
INTRODUCTION: Clozapine, a poorly tolerated antipsychotic drug, is widely recognized as the only efficacious option in treatment-resistant psychosis. The United Kingdom (U.K.) National Institute of Clinical Excellence (NICE) guidance for its consideration defined a threshold for treatment resistance substantially more liberal than that utilized in seminal studies of efficacy. This study documented adherence to NICE guidance in a patient group likely to be enriched for treatment resistance: 150 consecutive assertive outreach and former rehabilitation inpatients...
April 2010: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/20556756/concurrent-chemoradiotherapy-in-non-small-cell-lung-cancer
#9
REVIEW
Noelle O'Rourke, Marta Roqué I Figuls, Nuria Farré Bernadó, Fergus Macbeth
BACKGROUND: This is an updated version of the original review published in Issue 4, 2004. The use of concurrent chemotherapy and radiotherapy in non-small cell lung cancer (NSCLC) might be seen as a way of increasing the effectiveness of radical radiotherapy at the same time as reducing the risks of metastatic disease. OBJECTIVES: To determine the effectiveness of concurrent chemoradiotherapy as compared to radiotherapy alone with regard to overall survival, tumour control and treatment-related morbidity...
2010: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/20452752/efficacy-and-safety-of-daptomycin-in-the-treatment-of-gram-positive-catheter-related-bloodstream-infections-in-cancer-patients
#10
Anne-Marie Chaftari, Ray Hachem, Victor Mulanovich, Roy F Chemaly, Javier Adachi, Kalen Jacobson, Ying Jiang, Issam Raad
Excessive vancomycin usage has contributed to the emergence of vancomycin-resistant enterococci, and a high vancomycin minimal inhibitory concentration (MIC) >1.0 microg/mL has been associated with poor outcome in patients with meticillin-resistant Staphylococcus aureus (MRSA) infection. In view of these limitations, there is a need for an alternative agent. We evaluated the clinical efficacy and safety of daptomycin given as an alternative agent in the treatment of Gram-positive catheter-related bloodstream infections (CRBSIs) in cancer patients...
August 2010: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/20368818/a-phase-ii-study-of-weekly-paclitaxel-cisplatin-and-concurrent-radiation-therapy-for-locally-advanced-unresectable-non-small-cell-lung-cancer-early-closure-due-to-lack-of-efficacy
#11
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
PURPOSE: In this phase II study, the efficacy and safety of weekly paclitaxel concomitant with cisplatin and thoracic radiotherapy (TRT) was evaluated in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with stage III NSCLC (without pleural effusion or cervical lymphadenopathy) received TRT (63 Gy in 35 fractions over 7 weeks) with concurrent weekly cisplatin 20 mg/m(2) and paclitaxel 40 mg/m(2)/week infused over 3 hours...
October 2004: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/20051682/which-role-for-rituximab-in-hairy-cell-leukemia-reflections-on-six-cases
#12
REVIEW
J V Malfuson, T Fagot, J Konopacki, B Souleau, S Cremades, T de Revel
Hairy cell leukemia (HCL) is a rare, chronic, B-cell, lymphoproliferative disorder. Treatment has been revolutionized by the advent of interferon (IFN)-alpha and purine analogs (PA). First-line therapy with PA yields complete response rates of 75-100%, with many long-lasting remissions. In the event of profound neutropenia and/or infectious complications, a short sequence of IFN-alpha may precede PA treatment. Because of the excellent results achieved with PA therapy, the potential role of rituximab (an anti-CD20 monoclonal antibody that is highly effective against most B-cell lymphomas) in HCL has yet to be elucidated...
2010: Acta Haematologica
https://www.readbyqxmd.com/read/20015630/chest-low-dose-computed-tomography-in-neutropenic-acute-myeloid-leukaemia-patients
#13
COMPARATIVE STUDY
Demetris Patsios, Nimrod Maimon, TaeBong Chung, Heidi Roberts, Patricia Disperati, Mark Minden, Narinder Paul
BACKGROUND: We aimed to compare chest low-dose computed tomography (LDCT) with chest radiography (CXR) in the assessment of febrile acute myeloid leukaemia neutropenic patients. METHODS: A prospective non-randomized study was carried out between 30 May, 2003 and 3 June, 2004 in consecutive neutropenic patients who required imaging of the thorax and were treated for acute myeloid leukaemia. Each patient had a baseline 2-view chest radiograph followed by LDCT. Both the CXR and the LDCT studies were blindly and independently reviewed by two chest radiologists...
April 2010: Respiratory Medicine
https://www.readbyqxmd.com/read/19744230/imipenem-cilastatin-versus-piperacillin-tazobactam-as-monotherapy-in-febrile-neutropenia
#14
RANDOMIZED CONTROLLED TRIAL
Sema Vural, Ela Erdem, Seda Geylani Gulec, Yildiz Yildirmak, Rejin Kebudi
BACKGROUND: In view of the recent trend toward monotherapy in the treatment of febrile neutropenia, we evaluated the clinical efficacy and safety of imipenem-cilastatin versus piperacillin-tazobactam as an empiric therapy for febrile neutropenia in children with malignant diseases. METHODS: Febrile neutropenic patients received either imipenem-cilastatin or piperacillin-tazobactam randomly. Improvement without any changes in the initial antibiotic treatment was defined as "success" and improvement with modification of the initial treatment and death was defined as "failure"...
April 2010: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/19284419/infection-prevention-strategies-in-a-stem-cell-transplant-unit-impact-of-change-of-care-in-isolation-practice-and-routine-use-of-high-dose-intravenous-immunoglobulins-on-infectious-complications-and-transplant-related-mortality
#15
Nathan Cantoni, Maja Weisser, Andreas Buser, Caroline Arber, Martin Stern, Dominik Heim, Jörg Halter, Susanne Christen, Dimitrios A Tsakiris, Armin Droll, Reno Frei, Andreas F Widmer, Ursula Flückiger, Jakob Passweg, André Tichelli, Alois Gratwohl
OBJECTIVE: Nursing in 'live islands' and routine high dose intravenous immunoglobulins after allogeneic hematopoietic stem cell transplantation were abandoned by many teams in view of limited evidence and high costs. METHODS: This retrospective single-center study examines the impact of change from nursing in 'live islands' to care in single rooms (SR) and from high dose to targeted intravenous immunoglobulins (IVIG) on mortality and infection rate of adult patients receiving an allogeneic stem cell or bone marrow transplantation in two steps and three time cohorts (1993-1997, 1997-2000, 2000-2003)...
August 2009: European Journal of Haematology
https://www.readbyqxmd.com/read/19160254/granulocyte-transfusions-for-preventing-infections-in-patients-with-neutropenia-or-neutrophil-dysfunction
#16
REVIEW
Edwin Massey, Ulrike Paulus, Carolyn Doree, Simon Stanworth
BACKGROUND: Since the late 1990s there has been increasing demand for donated granulocyte transfusions to treat or prevent severe infections in patients who lack their own functional granulocytes. Other than in neonates, no systematic reviews have been performed for over 10 years relating to the efficacy of prophylactic granulocyte transfusions. OBJECTIVES: To determine the effectiveness and safety of granulocyte transfusions compared with a control population not receiving this intervention for preventing mortality due to infection or due to any other cause in patients with neutropenia or disorders of neutrophil function...
2009: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/18927527/pycnogenol-may-alleviate-adverse-effects-in-oncologic-treatment
#17
G Belcaro, M R Cesarone, D Genovesi, A Ledda, G Vinciguerra, A Ricci, L Pellegrini, G Gizzi, E Ippolito, M Dugall, M Cacchio, A Di Renzo, S Stuard
AIM: A large variety of adverse reactions are well known to frequently occur during chemotherapy and radiotherapy in oncology. Specific medications exist to target individual side effects. The aim of this study was to explore in a pilot trial whether supplementation with French maritime pine bark extract Pycnogenol could alleviate side effects and improve patient's quality of life. METHODS: Cancer patients who previously underwent surgery and who were in view of their pathology in relatively good condition, both physically and psychologically, were recruited for this study and divided into two groups...
September 2008: Panminerva Medica
https://www.readbyqxmd.com/read/17476588/multicenter-phase-ii-trial-of-genexol-pm-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-in-patients-with-metastatic-breast-cancer
#18
MULTICENTER STUDY
Keun Seok Lee, Hyun Cheol Chung, Seock Ah Im, Yeon Hee Park, Chul Soo Kim, Sung-Bae Kim, Sun Young Rha, Min Young Lee, Jungsil Ro
Genexol-PM is a novel Cremophor EL-free polymeric micelle formulation of paclitaxel. This single arm, multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM in patients with histologically confirmed metastatic breast cancer (MBC). Forty-one women received Genexol-PM by intravenous infusion at 300 mg/m2 over 3 h every 3 weeks without premedication until disease progression or intolerability. A total of 331 chemotherapy cycles were administered, with a median of 8 cycles per patient (range, 1-16)...
March 2008: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/17337226/bloodstream-infections-in-febrile-neutropenic-patients-at-a-tertiary-care-center-in-lebanon-a-view-of-the-past-decade
#19
Zeina A Kanafani, Ghenwa K Dakdouki, Khalil I El-Chammas, Shaker Eid, George F Araj, Souha S Kanj
OBJECTIVES: Previous studies from Lebanon have shown Gram-negative organisms to be the predominant agents in febrile neutropenic patients. The objective of this study was to evaluate the most current epidemiological trends among patients with neutropenic fever. METHODS: This prospective observational cohort study, the largest to date in the country, was conducted at the American University of Beirut Medical Center between January 2001 and December 2003, with the objective of describing the characteristics of patients with neutropenic fever and to assess temporal trends...
September 2007: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/15879624/a-phase-ii-study-of-capecitabine-plus-oxaliplatin-xelox-a-new-first-line-option-in-metastatic-colorectal-cancer
#20
Thomas Makatsoris, Haralabos P Kalofonos, Gerasimos Aravantinos, Christos Papadimitriou, Efstathios Kastritis, Sotirios K Rigatos, Nikolaos Xiros, Theodore Petsas, Theofanis Economopoulos, Athanassios K Sakadamis, George Fountzilas et al.
BACKGROUND: Capecitabine and oxaliplatin are both effective and well-tolerated monotherapies for the treatment of advanced colorectal cancer (CRC). Oxaliplatin has also been shown to be very effective when combined with 5-FU/LV in the first-line setting. AIM OF THE STUDY: Assess the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with previously untreated advanced CRC. METHODS: Fifty-three patients with measurable disease received capecitabine 1,000 mg/m2 twice daily on d 1-14 and oxaliplatin 130 mg/m2 on d 1, every 3 wk...
2005: International Journal of Gastrointestinal Cancer
keyword
keyword
97816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"